Aadi Bioscience Inc (AADI)

$2.11

Live

Performance

  • $2.09
    $2.14
    $2.11
    downward going graph

    0.91%

    Downside

    Day's Volatility :2.3%

    Upside

    1.4%

    downward going graph
  • $1.21
    $5.70
    $2.11
    downward going graph

    42.65%

    Downside

    52 Weeks Volatility :78.77%

    Upside

    62.98%

    downward going graph

Returns

PeriodAadi Bioscience IncIndex (Russel 2000)
3 Months
39.74%
0.0%
6 Months
11.05%
0.0%
1 Year
-46.45%
0.0%
3 Years
-92.14%
-23.0%

Highlights

Market Capitalization
53.2M
Book Value
$3.20
Earnings Per Share (EPS)
-2.43
Wall Street Target Price
1.63
Profit Margin
-274.77%
Operating Margin TTM
-252.21%
Return On Assets TTM
-34.93%
Return On Equity TTM
-62.26%
Revenue TTM
23.8M
Revenue Per Share TTM
0.88
Quarterly Revenue Growth YOY
-0.4%
Gross Profit TTM
-18.8M
EBITDA
-70.5M
Diluted Eps TTM
-2.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.02
EPS Estimate Next Year
-0.99
EPS Estimate Current Quarter
-0.69
EPS Estimate Next Quarter
-0.65

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Aadi Bioscience Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 22.75%

Current $2.11
Target $1.63

Company Financials

FY18Y/Y Change
Revenue
20.2M
-
Net Income
-10.4M
↓ 51.42%
Net Profit Margin
-51.58%
-
FY19Y/Y Change
Revenue
749.0K
↓ 96.28%
Net Income
-23.3M
↑ 123.83%
Net Profit Margin
-3.1K%
↓ 3055.3%
FY20Y/Y Change
Revenue
14.0M
↑ 1769.16%
Net Income
-3.5M
↓ 85.05%
Net Profit Margin
-24.84%
↑ 3082.04%
FY21Y/Y Change
Revenue
1000.0K
↓ 92.86%
Net Income
-110.1M
↑ 3065.32%
Net Profit Margin
-11.0K%
↓ 10984.16%
FY22Y/Y Change
Revenue
15.2M
↑ 1421.6%
Net Income
-57.0M
↓ 48.22%
Net Profit Margin
-374.67%
↑ 10634.33%
FY23Y/Y Change
Revenue
24.4M
↑ 60.06%
Net Income
-65.8M
↑ 15.36%
Net Profit Margin
-270.04%
↑ 104.63%
Q1 FY23Q/Q Change
Revenue
5.9M
↑ 12.24%
Net Income
-13.7M
↓ 1.67%
Net Profit Margin
-233.15%
↑ 33.01%
Q2 FY23Q/Q Change
Revenue
6.2M
↑ 5.71%
Net Income
-18.0M
↑ 31.38%
Net Profit Margin
-289.76%
↓ 56.61%
Q3 FY23Q/Q Change
Revenue
6.0M
↓ 3.92%
Net Income
-16.3M
↓ 9.29%
Net Profit Margin
-273.57%
↑ 16.19%
Q4 FY23Q/Q Change
Revenue
6.3M
↑ 6.16%
Net Income
-16.3M
↓ 0.2%
Net Profit Margin
-257.18%
↑ 16.39%
Q1 FY24Q/Q Change
Revenue
5.4M
↓ 15.38%
Net Income
-18.3M
↑ 12.42%
Net Profit Margin
-341.66%
↓ 84.48%
Q2 FY24Q/Q Change
Revenue
6.2M
↑ 15.43%
Net Income
-14.6M
↓ 20.26%
Net Profit Margin
-236.01%
↑ 105.65%
FY18Y/Y Change
Total Assets
64.1M
↑ 204.95%
Total Liabilities
5.5M
↑ 51.91%
FY19Y/Y Change
Total Assets
39.9M
↓ 37.72%
Total Liabilities
3.4M
↓ 37.67%
FY20Y/Y Change
Total Assets
18.8M
↓ 52.86%
Total Liabilities
31.3M
↑ 818.93%
FY21Y/Y Change
Total Assets
157.9M
↑ 738.83%
Total Liabilities
21.5M
↓ 31.2%
FY22Y/Y Change
Total Assets
184.2M
↑ 16.67%
Total Liabilities
25.9M
↑ 20.25%
FY23Y/Y Change
Total Assets
132.4M
↓ 28.12%
Total Liabilities
27.2M
↑ 5.29%
Q1 FY23Q/Q Change
Total Assets
170.7M
↓ 7.37%
Total Liabilities
24.7M
↓ 4.61%
Q2 FY23Q/Q Change
Total Assets
151.2M
↓ 11.38%
Total Liabilities
19.8M
↓ 19.7%
Q3 FY23Q/Q Change
Total Assets
139.7M
↓ 7.65%
Total Liabilities
21.5M
↑ 8.35%
Q4 FY23Q/Q Change
Total Assets
132.4M
↓ 5.18%
Total Liabilities
27.2M
↑ 26.86%
Q1 FY24Q/Q Change
Total Assets
111.1M
↓ 16.12%
Total Liabilities
20.6M
↓ 24.29%
Q2 FY24Q/Q Change
Total Assets
101.6M
↓ 8.51%
Total Liabilities
22.8M
↑ 10.75%
FY18Y/Y Change
Operating Cash Flow
-5.8M
↓ 69.24%
Investing Cash Flow
-37.9K
-
Financing Cash Flow
48.2M
↑ 28.53%
FY19Y/Y Change
Operating Cash Flow
-23.9M
↑ 310.68%
Investing Cash Flow
-35.7K
↓ 5.8%
Financing Cash Flow
8.1M
↓ 83.25%
FY20Y/Y Change
Operating Cash Flow
-12.7M
↓ 46.75%
Investing Cash Flow
-19.0K
↓ 46.73%
Financing Cash Flow
1.2M
↓ 85.21%
FY21Y/Y Change
Operating Cash Flow
-22.4M
↑ 76.55%
Investing Cash Flow
25.2M
↓ 132310.25%
Financing Cash Flow
141.8M
↑ 11776.38%
Q1 FY23Q/Q Change
Operating Cash Flow
-21.3M
↑ 88.42%
Investing Cash Flow
16.3M
↓ 119.35%
Financing Cash Flow
8.0K
↓ 107.48%
Q2 FY23Q/Q Change
Operating Cash Flow
-16.8M
↓ 21.36%
Investing Cash Flow
50.6M
↑ 209.64%
Financing Cash Flow
313.0K
↑ 3812.5%

Technicals Summary

Sell

Neutral

Buy

Aadi Bioscience Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aadi Bioscience Inc
Aadi Bioscience Inc
10.47%
11.05%
-46.45%
-92.14%
-91.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aadi Bioscience Inc
Aadi Bioscience Inc
NA
NA
NA
-2.02
-0.62
-0.35
NA
3.2
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aadi Bioscience Inc
Aadi Bioscience Inc
Buy
$53.2M
-91.88%
NA
-274.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Aadi Bioscience Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 5.35M → 6.17M (in $), with an average increase of 13.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -18.28M → -14.58M (in $), with an average increase of 25.4% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 131.3%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 136.9%

Institutional Holdings

  • venBio Select Advisor LLC

    11.58%

  • Longwood Capital Partners LLC

    7.51%

  • SATTER MANAGEMENT CO., L.P.

    6.63%

  • Vanguard Group Inc

    3.11%

  • Vivo Capital, LLC

    2.07%

  • Citadel Advisors Llc

    2.00%

Company Information

aadi bioscience inc. (aadi), is a rapidly growing biopharmaceutical company focused on the development and commercialization of precision medicines targeted to rare genomic alteration-driven cancers. aadi’s lead asset, fyarrotm (sirolimus albumin-bound nanoparticles for injectable suspension), is an mtor inhibitor targeting cancers driven by genetic alterations in mtor pathway genes. supported by leading healthcare investors, aadi is currently preparing for launch of fyarro in advanced malignant pecoma, a rare type of sarcoma with no previously approved therapies. aadi’s world class leadership team is comprised of industry veterans from top biotech companies who have proven track records of bringing blockbuster products to market. a science-first mindset and entrepreneurial spirit is in our genes. aadi’s vision to become a leading precision oncology company is further supported by ongoing work in tumor-agnostic biomarker-driven populations (e.g., pan tumor tsc1/2 alterations) and n

Organization
Aadi Bioscience Inc
Employees
70
CEO
Mr. David J. Lennon Ph.D.
Industry
Miscellaneous

Discover More

FAQs